HFE gene changes in obese individuals in Mosul
DOI:
https://doi.org/10.59480/phahs.v1i2.17Keywords:
HFEgene, obesity, CBC, Ferritin, total antioxidant capacityAbstract
Obesity represent one of major health problem worldwide in previous work in our laboratory significant change in iron status was notic. This study try to discover the relationship HFE gene copies number and obesity. This case control study included 90 subjects classified as 50 obese and 50 normal weight as the control group. Their ages ranged from 12 to 22 years old and carried out in Mosul during the period of April to June 2022. Complete blood picture was used to study the change in blood parameters. In addition serum ferritin was evaluated using ELISA kit.Gene copies number was assess using the GoTaq qPCR. The results of this work showed that in obese patients highest levels of hemoglobin found in compare to control (p<0.05) As observed in patients leukocyte level was which significantly higher than control p<0.05. Elevated levels of Platlate were observed in a significant higher proportion of patients than controls, Neutrophil and Lymphocyte also showed a significantly higher level in obese than control. High serum ferritin levels in obese individuals was observe in compare to controls. There was significant increase in the number of copies of the HFE gene in obese patients compare controls. In conclusion, HFE gene copies number increase in obese individuals as compensatory mechanism.
References
Adams, P. C., McLaren, C. E., Speechley, M., McLaren, G. D., Barton, J. C., & Eckfeldt, J. H. (2013). HFE Mutations in Caucasian Participants of the Hemochromatosis and Iron Overload Screening Study with Serum Ferritin Level. Canadian Journal of Gastroenterology, 27(7), 390-392.
Alessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., ... & Juhan-Vague, I. (2000). Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes, 49(8), 1374-1380.
AL-Kataan, M. A. G. (2013). Iron status in metabolic syndrome. Iraqi Journal of Pharmacy, 13(1).
Aranda, N., Bedmar, C., Arija, V., Jardí, C., Jimenez-Feijoo, R., Ferré, N., & Tous, M. (2018). Serum hepcidin levels, iron status, and HFE gene alterations during the first year of life in healthy Spanish infants. Annals of Hematology, 97(6), 1071-1080.
Araujo, J. A., Romano, E. L., Brito, B. E., Parthé, V., Romano, M., Bracho, M., ... & Cardier, J. (1995). Iron overload augments the development of atherosclerotic lesions in rabbits. Arteriosclerosis, thrombosis, and vascular biology, 15(8), 1172-1180.
Barisani, D., Pelucchi, S., Mariani, R., Galimberti, S., Trombini, P., Fumagalli, D., ... & Piperno, A. (2008). Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. Journal of hepatology, 49(1), 123-133.
Barton, J. C., & Edwards, C. Q. (1993). HFE Hemochromatosis. 2000 Apr 3 [updated 2018 Dec 6]. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle, 2020.
Barton, J. C., Edwards, C. Q., & Acton, R. T. (2015). HFE gene: structure, function, mutations, and associated iron abnormalities. Gene, 574(2), 179-192.
Bassett, M. L., Halliday, J. W., Ferris, R. A., & Powell, L. W. (1984). Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology, 87(3), 628-633.
Beutler E (2006) Hemochromatosis: genetics and pathophysiology. Annu Rev Med 57:331–347.
Chung, G. E., Yim, J. Y., Kim, D., Kwak, M. S., Yang, J. I., Chung, S. J., ... & Kim, J. S. (2017). Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. Digestive and Liver Disease, 49(1), 57-62.
Dandona, P., Aljada, A., & Bandyopadhyay, A. (2004). Inflammation: the link between insulin resistance, obesity and diabetes. Trends in immunology, 25(1), 4-7.
Datz, C., Felder, T. K., Niederseer, D., & Aigner, E. (2013). Iron homeostasis in the metabolic syndrome. European journal of clinical investigation, 43(2), 215-224.
Deugnier, Y., Morcet, J., Lainé, F., Hamdi-Roze, H., Bollard, A. S., Guyader, D., ... & Bardou-Jacquet, E. (2019). Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers. Journal of Hepatology, 70(1), 118-125.
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., ... & Wolff, R. K. (1996). A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis. Nature genetics, 13(4), 399-408.
González-Domínguez, Á., Visiedo-García, F. M., Domínguez-Riscart, J., González-Domínguez, R., Mateos, R. M., & Lechuga-Sancho, A. M. (2020). Iron metabolism in obesity and metabolic syndrome. International journal of molecular sciences, 21(15), 5529.
Hämäläinen, P., Saltevo, J., Kautiainen, H., Mäntyselkä, P., & Vanhala, M. (2012). Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovascular diabetology, 11(1), 1-8.
Hanson, E. H., Imperatore, G., & Burke, W. (2001). HFE gene and hereditary hemochromatosis: a HuGE review. American journal of epidemiology, 154(3), 193-206.
Hashimoto, Y., Tanaka, M., Kimura, T., Kitagawa, N., Hamaguchi, M., Asano, M., ... & Fukui, M. (2015). Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study. Endocrine, 50(2), 390-396.
He, S., Gu, H., Yang, J., Su, Q., Li, X., & Qin, L. (2021). Hemoglobin concentration is associated with the incidence of metabolic syndrome. BMC Endocrine Disorders, 21(1), 1-11.
Huang X (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 533:153–171.
Kew, M. C. (2014). Hepatic iron overload and hepatocellular carcinoma. Liver cancer, 3(1), 31-40.
Kowdley KV, Bennett RL, Motulsky AG. HFE – Associated Hereditary Hemochromatosis. GeneReviews; Avaliable at http://www.ncbi.nlm.nih.gov/books/NBK1440. (Accessed June 10, 2013).
Lee, P., Peng, H., Gelbart, T., & Beutler, E. (2004). The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and β2-microglobulin-deficient hepatocytes. Proceedings of the National Academy of Sciences, 101(25), 9263-9265.
Leiva, E., Mujica, V., Sepúlveda, P., Guzmán, L., Núñez, S., Orrego, R., ... & Arredondo, M. A. (2013). High levels of iron status and oxidative stress in patients with metabolic syndrome. Biological trace element research, 151(1), 1-8.
Lin, L., Valore, E. V., Nemeth, E., Goodnough, J. B., Gabayan, V., & Ganz, T. (2007). Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, The Journal of the American Society of Hematology, 110(6), 2182-2189.
Milman, N. T., Schioedt, F. V., Junker, A. E., & Magnussen, K. (2019). Diagnosis and treatment of genetic HFE-hemochromatosis: the Danish aspect. Gastroenterology Research, 12(5), 221.
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., ... & Coppack, S. W. (1997). Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. The Journal of Clinical Endocrinology & Metabolism, 82(12), 4196-4200.
Moris, W., Verhaegh, P. L., Masclee, A. A., Swinkels, D. W., Laarakkers, C. M., Koek, G. H., & van Deursen, C. T. B. (2021). Inflammation can increase hepcidin in HFE‐hereditary hemochromatosis. Clinical Case Reports, 9(5), e04114.
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of clinical investigation, 113(9), 1271-1276.
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003). Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, The Journal of the American Society of Hematology, 101(7), 2461-2463.
Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., ... & Vaulont, S. (2002). The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. The Journal of clinical investigation, 110(7), 1037-1044.
Pedersen, P., & Milman, N. (2009). Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Annals of hematology, 88(8), 775-784.
Pietrangelo, A., Deugnier, Y., Dooley, J., Erhardt, A., Zoller, H., & Safadi, R. (2010). EASL clinical practice guidelines for HFE hemochromatosis. Journal of hepatology, 53(1), 3-22.
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001). A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. Journal of biological chemistry, 276(11), 7811-7819.
Prabhu, A., Cargill, T., Roberts, N., & Ryan, J. D. (2020). Systematic review of the clinical outcomes of iron reduction in hereditary hemochromatosis. Hepatology, 72(4), 1469-1482.
Robinson, J. P., Johnson, V. L., Rogers, P. A., Houlston, R. S., Maher, E. R., Bishop, D. T., ... & Colorectal Cancer Gene Identification (CORGI) consortium. (2005). Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiology Biomarkers & Prevention, 14(6), 1460-1463.
Rodríguez-Mortera, R., Caccavello, R., Hermo, R., Garay-Sevilla, M. E., & Gugliucci, A. (2021). Higher hepcidin levels in adolescents with obesity are associated with metabolic syndrome dyslipidemia and visceral fat. Antioxidants, 10(5), 751.
Roy, C. N., Custodio, Á. O., De Graaf, J., Schneider, S., Akpan, I., Montross, L. K., ... & Muckenthaler, M. U. (2004). An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nature genetics, 36(5), 481-485.
Ryder, E., Diez-Ewald, M., Mosquera, J., Fernández, E., Pedreañez, A., Vargas, R., ... & Fernández, N. (2014). Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 8(4), 197-204.
Sanad, M., Osman, M., & Gharib, A. (2011). Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: a case control study. Italian journal of pediatrics, 37(1), 1-6.
Shim, Y. S., Kang, M. J., Oh, Y. J., Baek, J. W., Yang, S., & Hwang, I. T. (2017). Association of serum ferritin with insulin resistance, abdominal obesity, and metabolic syndrome in Korean adolescent and adults: The Korean National Health and Nutrition Examination Survey, 2008 to 2011. Medicine, 96(8).
Suárez-Ortegón, M. F., Ensaldo-Carrasco, E., Shi, T., McLachlan, S., Fernández-Real, J. M., & Wild, S. H. (2018). Ferritin, metabolic syndrome and its components: a systematic review and meta-analysis. Atherosclerosis, 275, 97-106.
Sullivan JL (1981) Iron and the sex difference in heart disease risk. Lancet 1:1293–1294
Trinder, D., Fox, C., Vautier, G., & Olynyk, J. K. (2002). Molecular pathogenesis of iron overload. Gut, 51(2), 290-295.
Weiss, G. (2005). Modification of iron regulation by the inflammatory response. Best practice & research Clinical haematology, 18(2), 183-201.
Whittington, C.A., Kowdley, K.V.(2002).Review article: Haemochromatosis. Aliment Pharmacol Ther 2002;16:1963–1975.
WHO Technical Series (2000) Obesity: Preventing and managing the global epidemic. Report of a WHO con-sultation. World Health Organization Technical Report Series, 894, 1-253.
Wong, K., & Adams, P. C. (2006). The diversity of liver diseases among outpatient referrals for elevated serum ferritin. Canadian journal of gastroenterology, 20(7), 467-470.
Yuan XM, Li W (2008) Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 15:2157–2172.
Zhang, H., Wang, L., Li, S., Liu, X., Li, Y., He, Y., ... & Yang, L. (2020). Association of iron storage markers with metabolic syndrome and its components in Chinese rural 6–12 years old children: the 2010–2012 China National Nutrition and Health Survey. Nutrients, 12(5), 1486.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Tamarah N. Qasim, Muhammad Ahmed Ahmed Al Kataan, Mwafk K. Hasan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All PHAHS Journal articles are published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) which allows authors retain copyright and others may not use the material for commercial purposes. A commercial use is one primarily intended for commercial advantage or monetary compensation. If others remix, transform, or build upon the material, they may not distribute the modified material.
Copyright on any research article published by the PHAHS Open Access journal is retained by the author(s). Authors also grant any third party the right to use the article freely as long as its original authors, citation details and publisher are identified.
Use of the article in whole or part in any medium requires attribution suitable in form and content as follows: [Title of Article/Author/Journal Title and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the Journal]. Links to the final article on PHAHS website are encouraged where applicable.
The CC BY-NC-ND 4.0 Creative Commons Attribution License does not affect the moral rights of authors, including without limitation the right not to have their work subjected to derogatory treatment. It also does not affect any other rights held by authors or third parties in the article, including trademark or patent rights, or the rights of privacy and publicity. Use of the article must not assert or imply, whether implicitly or explicitly, any connection with, endorsement or sponsorship of such use by the author, publisher or any other party associated with the article.
Pharmacy and Applied Health Science: A Scientific Periodical Open Access Journal and has no APC & ASC.